Compare Ecopetrol SA (EC) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Natera Inc. Common Stock — how do they compare? Ecopetrol SA trades at $18 (market cap $33.52B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Ecopetrol SA pays a 3.71% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Natera Inc. Common Stock for 0 Days on average.
| EC | NTRA | |
|---|---|---|
Market Cap | $33.52B | $57.03B |
Volume | 1,602,222 | 1,131,157 |
Sector | Energy | Health |
52-Week High | $18.26 | $425.64 |
52-Week Low | $8.61 | $179.42 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $62.13B | $56.18B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $17.90, up 3.89% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. Revenue has declined from $159.61T in 2022 to $119.69T in 2025, with net income margin falling to 8.76%. Recent management changes and board appointments signal corporate transformation efforts, while analyst consensus is cautious with a 'Reduce' rating and $16.85 price target.
The stock faces headwinds from declining profitability and revenue, offset by low valuation multiples (P/E 8.27, EV/EBITDA 4). Risks include political influence, corruption probes, and oil price volatility. Upside depends on execution under new leadership and stabilization of financials, but current sentiment remains neutral to bearish amid operational challenges.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
